Selecta Biosciences (NASDAQ:SELB) Shares Up 5.8%

Selecta Biosciences Inc (NASDAQ:SELB)’s share price shot up 5.8% on Tuesday . The stock traded as high as $1.69 and last traded at $1.65, 709,857 shares were traded during trading. An increase of 341% from the average session volume of 160,975 shares. The stock had previously closed at $1.56.

Several research firms have weighed in on SELB. Zacks Investment Research downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Selecta Biosciences in a report on Friday, November 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Selecta Biosciences in a report on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $6.80.

The stock has a fifty day simple moving average of $1.49 and a two-hundred day simple moving average of $1.74. The company has a market cap of $75.19 million, a PE ratio of -0.55 and a beta of 1.17.

Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. On average, equities analysts expect that Selecta Biosciences Inc will post -1.23 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its holdings in Selecta Biosciences by 582.4% in the 2nd quarter. Morgan Stanley now owns 63,784 shares of the company’s stock valued at $114,000 after acquiring an additional 54,437 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Selecta Biosciences in the 2nd quarter valued at $31,000. Vanguard Group Inc. raised its holdings in Selecta Biosciences by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,620,305 shares of the company’s stock valued at $2,901,000 after acquiring an additional 109,806 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Selecta Biosciences by 98.4% in the 2nd quarter. Renaissance Technologies LLC now owns 471,500 shares of the company’s stock valued at $844,000 after acquiring an additional 233,800 shares during the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in Selecta Biosciences in the 2nd quarter valued at $40,000. 39.55% of the stock is currently owned by institutional investors.

About Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

Recommended Story: What is a front-end load?

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.